Literature DB >> 7856749

Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors.

E Hatva1, A Kaipainen, P Mentula, J Jääskeläinen, A Paetau, M Haltia, K Alitalo.   

Abstract

Key growth factor-receptor interactions involved in angiogenesis are possible targets for therapy of CNS tumors. Vascular endothelial growth factor (VEGF) is a highly specific endothelial cell mitogen that has been shown to stimulate angiogenesis, a requirement for solid tumor growth. The expression of VEGF, the closely related placental growth factor (PIGF), the newly cloned endothelial high affinity VEGF receptors KDR and FLT1, and the endothelial orphan receptors FLT4 and Tie were analyzed by in situ hybridization in normal human brain tissue and in the following CNS tumors: gliomas, grades II, III, IV; meningiomas, grades I and II; and melanoma metastases to the cerebrum. VEGF mRNA was up-regulated in the majority of low grade tumors studied and was highly expressed in cells of malignant gliomas. Significantly elevated levels of Tie, KDR, and FLT1 mRNAs, but not FLT4 mRNA, were observed in malignant tumor endothelia, as well as in endothelia of tissues directly adjacent to the tumor margin. In comparison, there was little or no receptor expression in normal brain vasculature. Our results are consistent with the hypothesis that these endothelial receptors are induced during tumor progression and may play a role in tumor angiogenesis.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7856749      PMCID: PMC1869858     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  37 in total

Review 1.  Angiogenesis.

Authors:  J Folkman; Y Shing
Journal:  J Biol Chem       Date:  1992-06-05       Impact factor: 5.157

2.  Enhanced expression of the tie receptor tyrosine kinase in endothelial cells during neovascularization.

Authors:  J Korhonen; J Partanen; E Armstrong; A Vaahtokari; K Elenius; M Jalkanen; K Alitalo
Journal:  Blood       Date:  1992-11-15       Impact factor: 22.113

3.  tek, a novel tyrosine kinase gene located on mouse chromosome 4, is expressed in endothelial cells and their presumptive precursors.

Authors:  D J Dumont; T P Yamaguchi; R A Conlon; J Rossant; M L Breitman
Journal:  Oncogene       Date:  1992-08       Impact factor: 9.867

4.  FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

Authors:  K Pajusola; O Aprelikova; J Korhonen; A Kaipainen; L Pertovaara; R Alitalo; K Alitalo
Journal:  Cancer Res       Date:  1992-10-15       Impact factor: 12.701

5.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.

Authors:  D Shweiki; A Itin; D Soffer; E Keshet
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

6.  Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer.

Authors:  E R Horak; R Leek; N Klenk; S LeJeune; K Smith; N Stuart; M Greenall; K Stepniewska; A L Harris
Journal:  Lancet       Date:  1992-11-07       Impact factor: 79.321

7.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo.

Authors:  K H Plate; G Breier; H A Weich; W Risau
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

8.  Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms.

Authors:  R A Berkman; M J Merrill; W C Reinhold; W T Monacci; A Saxena; W C Clark; J T Robertson; I U Ali; E H Oldfield
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

9.  Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.

Authors:  B I Terman; M Dougher-Vermazen; M E Carrion; D Dimitrov; D C Armellino; D Gospodarowicz; P Böhlen
Journal:  Biochem Biophys Res Commun       Date:  1992-09-30       Impact factor: 3.575

10.  The related FLT4, FLT1, and KDR receptor tyrosine kinases show distinct expression patterns in human fetal endothelial cells.

Authors:  A Kaipainen; J Korhonen; K Pajusola; O Aprelikova; M G Persico; B I Terman; K Alitalo
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  44 in total

Review 1.  Intravital fluorescence videomicroscopy to study tumor angiogenesis and microcirculation.

Authors:  P Vajkoczy; A Ullrich; M D Menger
Journal:  Neoplasia       Date:  2000 Jan-Apr       Impact factor: 5.715

Review 2.  Role of vascular permeability factor/vascular endothelial growth factor in eye disease.

Authors:  R O Schlingemann; V W van Hinsbergh
Journal:  Br J Ophthalmol       Date:  1997-06       Impact factor: 4.638

3.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.

Authors:  P Lin; P Polverini; M Dewhirst; S Shan; P S Rao; K Peters
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 4.  Is angiopoietin-2 necessary for the initiation of tumor angiogenesis?

Authors:  J Laurén; Y Gunji; K Alitalo
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

Review 5.  Angiogenesis in transgenic models of multistep carcinogenesis.

Authors:  M G D' Angelo; T Afanasieva; A Aguzzi
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 6.  Vascular microenvironment in gliomas.

Authors:  P Vajkoczy; M D Menger
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

Review 7.  VEGF in brain tumors.

Authors:  M R Machein; K H Plate
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

8.  Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy.

Authors:  Gabriela D'Amico; Emilia A Korhonen; Andrey Anisimov; Georgia Zarkada; Tanja Holopainen; René Hägerling; Friedemann Kiefer; Lauri Eklund; Raija Sormunen; Harri Elamaa; Rolf A Brekken; Ralf H Adams; Gou Young Koh; Pipsa Saharinen; Kari Alitalo
Journal:  J Clin Invest       Date:  2014-01-16       Impact factor: 14.808

9.  Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas.

Authors:  Matthias A Karajannis; Geneviève Legault; Michael J Fisher; Sarah S Milla; Kenneth J Cohen; Jeffrey H Wisoff; David H Harter; Judith D Goldberg; Tsivia Hochman; Amanda Merkelson; Michael C Bloom; Angela J Sievert; Adam C Resnick; Girish Dhall; David T W Jones; Andrey Korshunov; Stefan M Pfister; Charles G Eberhart; David Zagzag; Jeffrey C Allen
Journal:  Neuro Oncol       Date:  2014-05-06       Impact factor: 12.300

10.  Spatial expression of VEGF-A in human glioma.

Authors:  Mikael Johansson; Thomas Brännström; A Tommy Bergenheim; Roger Henriksson
Journal:  J Neurooncol       Date:  2002-08       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.